SynthesisCurrent cardiology reports2020
Reasons Why Combination Therapy Should Be the New Standard of Care to Achieve the LDL-Cholesterol Targets : Lipid-lowering combination therapy.
Synthesis in Current cardiology reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 1 synthesis or guideline pooled it, 54 citations in OpenAlex.
- [Cardiovascular preventive recommendations. PAPPS 2024 thematic updates].Atencion primaria · 2024Guideline
- Effects of evolocumab combined with statin therapy on blood lipids, inflammatory factors, and endothelial function in patients with coronary heart disease.BMC cardiovascular disorders · 2026Article
- Advancing Lipid Management: Saudi Heart Association Position Statement on PCSK9-targeted Therapies in the Primary and Secondary Prevention of Cardiovascular Disease.Journal of the Saudi Heart Association · 2026Article
- Chinese expert consensus on the choice of initial cholesterol-lowering strategy.Frontiers in pharmacology · 2026Review
- Early Management of Blood Lipid Levels with Non-Statin Lipid-Lowering Drugs in Acute Coronary Syndrome: A Mini Review.Cardiovascular drugs and therapy · 2025Review
- Expert opinion on the integration of combination therapy into the treatment algorithm for the management of dyslipidaemia: the integration of ezetimibe and bempedoic acid may enhance goal attainment.European heart journal. Cardiovascular pharmacotherapy · 2025Review
- Considerations on the sustainability of hypercholesterolemia treatment in the context of new drugs on the market: data from Campania, Italy.Naunyn-Schmiedeberg's archives of pharmacology · 2025Article
- Low-Density Lipoprotein Cholesterol Reduction and Therapeutic Adherence During Cardiac Rehabilitation After Myocardial Infarction.Journal of clinical medicine · 2025Article
- LDL-C Reduction with Evolocumab Among Patients with ASCVD in China: Real-World Evidence from Tianjin Metropolitan Area.Advances in therapy · 2025Article
- Therapeutic Inertia in Dyslipidemia Management for Secondary Cardiovascular Prevention: Results from the Italian ITACARE-P Network.Journal of clinical medicine · 2025Article
- Optimisation of lipid-lowering therapy post-Acute Coronary Syndromes: a multidisciplinary, cross-interface novel pharmacy care model within a local cardiac rehabilitation centre.Journal of pharmaceutical policy and practice · 2025Article
- Article
- Real-world evidence evaluation of LDL-C in hospitalized patients: a population-based observational study in the timeframe 2021-2022.Lipids in health and disease · 2024Observational
- Emerging therapies for refractory hypercholesterolemia: a narrative review.Future cardiology · 2024Review
- Lipid-lowering approaches to manage statin-intolerant patients.European heart journal supplements : journal of the European Society of Cardiology · 2024Article
- Evolocumab effectiveness in the real-world setting: Austrian data from the pan-European observational HEYMANS study.Wiener klinische Wochenschrift · 2024Observational
- Uncontrolled Cholesterol in Individuals with Severe Hypercholesterolemia in a Health Evaluation Program in Brazil.Arquivos brasileiros de cardiologia · 2024Article
- A retrospective nationwide analysis of evolocumab use in Sweden and its effect on low-density lipoprotein cholesterol levels.Upsala journal of medical sciences · 2024Article
- Short-Course High-Intensity Statin Treatment during Admission for Myocardial Infarction and LDL-Cholesterol Reduction-Impact on Tailored Lipid-Lowering Therapy at Discharge.Journal of clinical medicine · 2023Article
- Decoding microRNA drivers in atherosclerosis.Bioscience reports · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewThe aim of this report is to review the scientific evidence supporting that lipid lowering therapy (LLT), beyond statins, reduces cardiovascular risk; therefore, treatment strategies based on lipid-lowering drug combination should be implemented. RECENT
findingsA strong scientific body of evidence supports the effect of statins on cardiovascular risk reduction. Recent trials using non-statin LLT, ezetimibe, and PCSK9 inhibitors have provide scientific evidence about their impact on cardiovascular prevention. Current clinical guidelines still recommend using high-intensity statin monotherapy before considering combination therapy. The causal effect of LDL-C on atherosclerosis is well established. Moreover, new RCT, meta-analysis, and Mendelian randomization data, support that the main determinant of risk reduction is the absolute LDL reduction regardless of LLT. Accordingly, the "high-intensity statin therapy" concept should be substituted by "high-intensity lipid lowering therapy." Combination therapy must become the standard of care of hypercholesterolemia treatment.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.